ReNeuron Group plc
RNUGF · OTC
9/30/2023 | 3/31/2023 | 9/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | 0.05 | 0.06 |
| FCF Yield | -49.81% | -77.33% | -25.59% | -17.29% |
| EV / EBITDA | 0.16 | 0.57 | -4.20 | -3.09 |
| Quality | ||||
| ROIC | -105.00% | -40.77% | -46.92% | -43.17% |
| Gross Margin | -1,286.62% | -1,505.43% | 69.86% | 57.10% |
| Cash Conversion Ratio | 0.74 | 1.42 | 1.35 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -52.49% | -36.34% | -36.88% | -28.39% |
| Free Cash Flow Growth | 34.85% | 27.48% | -55.87% | 40.98% |
| Safety | ||||
| Net Debt / EBITDA | 1.47 | 2.08 | 4.47 | 3.70 |
| Interest Coverage | -206.25 | 0.00 | -427.40 | -736.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.88 | 0.00 | -0.08 |
| Cash Conversion Cycle | 30.53 | 367.02 | -4,166.98 | -1,478.96 |